Dr. DeOrchis and NKMAX partner to obtain FDA clearance for experimental Alzheimer‘s disease drug for compassionate use in U.S.

As reported in Pulse News, “NKMAX, a NK cell-based immunotherapy company in Korea, Wednesday said an investigational cell therapeutic SNK01 from its subsidiary NKGen Biotech (formerly NKMAX America) has received approval from the U.S. Food and Drug Administration (FDA) for patients with Alzheimer’s disease in compassionate use programs…Approval was given to Dr. Vincent Deorchis of St. Francis Hospital in New York, and he will use SNK01 for the treatment of eligible patients.” The remainder of the story can be found on Pulse News website:

NKMAX’ Alzheimer‘s disease drug cleared for compassionate use in U.S.